ArticleFrontiers in pharmacology2026
Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: By 2021, regulatory agencies had approved two glucagon-like peptide-1 receptor agonists (GLP-1RAs), semaglutide and liraglutide, for the treatment of type 2 diabetes and obesity. Since then, concerns have emerged about whether adverse events (AEs) differ by GLP-1RA or indication. Research design and methods: We analyzed the Food and Drug Administration Adverse Event Reporting System (FAERS) reports (2021-2025) to compare adverse events associated with semaglutide and liraglutide indications. Comparisons with metformin and orlistat helped distinguish drug-related signals from disease-related signals. We defined safety signals by a positive reporting odds ratio and at least one other positive disproportionality metric. Results: Among 8,213,105 FAERS reports, 33,259 met the inclusion criteria. Semaglutide generated more reports for type 2 diabetes than for obesity (13,168 vs. 5,444), and liraglutide showed a similar pattern (1,201 vs. 837). GLP-1RAs exhibited gastrointestinal AEs. Semaglutide showed signals for slowed gastrointestinal motility across both indications, particularly impaired gastric emptying, in both type 2 diabetes and obesity reports (ROR = 8.35, 95% CI = 1.16-59.97 and ROR = 4.01, 95% CI = 2.12-7.58, respectively). Liraglutide demonstrated signals for more severe gastrointestinal AEs, including abdominal distention in type 2 diabetes (ROR = 1.46, 95% CI = 1.12-1.91) and pancreatitis in obesity (ROR = 2.90, 95% CI = 1.91-4.39) reports. Additional notable safety signals included optic ischemic neuropathy with semaglutide (ROR = 4.42, 95% CI = 1.41-13.87) and psychiatric AEs, including suicidal ideation (ROR = 5.98, 95% CI = 1.24-24.19). Conclusion: We identified robust signals for GLP-1RAs, including impaired gastric emptying, ileus, and ischemic optic neuropathy. Additionally, we identified signals for suicidal ideation. Future studies are needed to evaluate for causal relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.